Product Description
Empagliflozin 25mg Tablets: What the Published Guidance Says
Human and analogue insulins alongside the oral hypoglycaemics and cardiorenal-metabolic agents added to the WHO Model List in its September 2025 revision.
Empagliflozin 25mg Tablets sits in the Diabetes & Insulin range. The notes below are the ones that most often change a specification, a label or a tender submission.
- SGLT2 inhibitors are on the Model List Section 18.5.2 lists empagliflozin as a 10 mg and 25 mg tablet for type 2 diabetes mellitus, with canagliflozin and dapagliflozin named as therapeutic equivalents. WHO eEML — Medicines for diabetes
- September 2025 added the GLP-1 class WHO added the GLP-1 receptor agonists semaglutide, dulaglutide and liraglutide, and the dual GLP-1/GIP agonist tirzepatide, for adults with type 2 diabetes where cardiovascular disease or chronic kidney disease is established and obesity is present (BMI ≥ 30 kg/m²). WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
- The Model List details the insulin presentations and strengths Section 18.5.1 of the 24th WHO Model List (2025) lists human short-acting insulin as an injection solution of 40 IU/mL or 100 IU/mL in 10 mL vials and 100 IU/mL in 3 mL cartridges or pre-filled pens. Human intermediate-acting insulin is listed as an injection suspension in the same strengths, as compound insulin zinc suspension or isophane insulin. Long-acting and rapid-acting analogues are listed with glargine, degludec and detemir named among the therapeutic alternatives — a footnote notes that quality-assured biosimilars are included. WHO eEML — Medicines for diabetes
These points are quoted because they shape how Empagliflozin 25mg Tablets is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.
Ordering Parameters for Empagliflozin 25mg Tablets
| Product Name | Empagliflozin Tablets (Empagliflozin 25mg Oral Tablets) |
| Specification | Each tablet contains: Empagliflozin 25mg |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredient | Empagliflozin |
| Pharmacological Class | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Antidiabetic Agent) |
| Route of Administration | Oral administration (swallowed whole with water; take at approximately the same time each morning, with or without food). |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | Diabetes & Insulin — Diabetes & Insulin |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Dapagliflozin 10mg Tablets, Canagliflozin 300mg Tablets, Ertugliflozin 15mg Tablets, Finerenone 20mg Tablets, Repaglinide Tablets 2mg, Sotagliflozin 400mg Tablets, Mixed Protamine Human Insulin 30R, Insulin Glargine Injection 100IU/mL 3ml Cartridge.
Pharmacopoeial Standard, Release Testing & COA
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Empagliflozin 25mg Tablets is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The quality control package for the marketed pack covers:
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packing, Labelling Languages & Export Paperwork
- Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Marketing Authorisation & Tender Support
Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
This page describes Empagliflozin 25mg Tablets as a product of the medicines for diabetes listed in the WHO Model List family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.
Empagliflozin 25mg Tablets: Common Procurement Questions
What pack size is available for Empagliflozin 25mg Tablets?
The reference pack is Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.
What documentation comes with a shipment of Empagliflozin 25mg Tablets?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months.
Does the batch documentation for Empagliflozin 25mg Tablets support a registration filing?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Can you support an insulin registration dossier?
Yes — we provide DMF and dossier packages with registration support documents. DML Number Jin20160068 covers medicines production.
Do you supply human insulin as well as analogues?
Yes. We supply human short-acting, isophane and premixed 30/70 protamine human insulin, and insulin glargine. The Model List notes that quality-assured biosimilars are included in its analogue listings.
Products Commonly Ordered with Empagliflozin 25mg Tablets
- Dapagliflozin 10mg Tablets — 10mg
- Canagliflozin 300mg Tablets — 300mg
- Ertugliflozin 15mg Tablets — 15mg
- Finerenone 20mg Tablets — 20mg
- Repaglinide Tablets 2mg — 2mg
- Sotagliflozin 400mg Tablets — 400mg
Browse the full Diabetes & Insulin range; all Tablets; the complete product catalogue.
Request a Quotation for Empagliflozin 25mg Tablets
Send the specification, pack size, quantity and destination market for Empagliflozin 25mg Tablets 25mg and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.
Sources & Regulatory Notes
- WHO eEML — Medicines for diabetes
- WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
